We feature Hair loss treatment and hair regrowth formulations.

Hair restoration in the ethnic patient and review of hair transplant fundamentals.
Lam SM, Karamanovski E.

Willow Bend Wellness Center, Lam Facial Plastic Surgery Center and Hair Restoration Institute, Plano, TX 75093, USA.

Abstract
Superior hair restoration requires the application of universal principles along with variations that apply to specific ethnic populations. This article serves as a primer on basic tenets of hair restoration, with additional attention given to the uniqueness and differences in technique and design that are warranted for a wide range of races and ethnicities. This article also gives prospective surgeons an insight on how to undertake further study and shore up their deficiencies so as to refine knowledge gaps and ensure patient safety and excellent surgical outcomes.

Edited for Hairloss treatment blog

Vitiligo after diphencyprone for alopecia areata.
Pires MC, Martins JM, Montealegre F, Gatti FR.

slightly edited for hair loss blog use

Abstract
The topical immunotherapy is used to treat alopecia areata and recalcitrant warts since the 1970s. Diphencyprone is a contact sensitizer used to treat dermatological conditions resulting from as altered immunological state, such as extensive alopecia areata, being partially effective and safe. Side effects include local eczema with blistering, regional lymphadenopathy and contact urticaria. Rare adverse effects include an erythema multiforme-like reaction, hyperpigmenttion, hypopigmentation, and vitiligo. We report a 30-year-old, Brazilian male who developed vitiligo lesions following DPCP therapy for hair loss in alopecia areata.

Hair loss blog

Hair loss treatment blog

Hair loss blog

Hair loss treatment blog

Hair loss treatment blog

Hair loss blog

Redox signaling blog

Copyright © Indian Journal of Dermatology
COMPARATIVE ASSESSMENT OF TOPICAL STEROIDS, TOPICAL TRETENOIN (0.05%) AND DITHRANOL PASTE IN ALOPECIA AREATA
Sudip Das, R C Ghorami, T Chatterjee, and Gautam Banerjee1
Bankura Sammilani Medical College, Bankura, West Bengal, India
1IPGMER, Kolkata, India.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

AbstractIntroductionMaterials and MethodsResultsDiscussionReferencesAbstractBackground:
There have been various controversial reports regarding the efficacy of topical agents in topical therapy of alopecia areata.

Aim: The study aims to find out the effective ones among the readily available ones for a dermatologist.

Materials and Methods: Eighty patients were chosen from the skin OPD of Bankura Sammilani Medical College, Bankura, West Bengal, after evaluating the exclusion criterions. Treatments were continued for 3 month period and a follow up after further 3 months. After dividing them into four groups–group-I (topical steroids), group-II (topical tretinoin 0.05%) group-III (dithranol paste 0.25%), and group-IV (white soft petrolatum jelly)–patients were evaluated.

Results: Seventy percent of group-I, 55% of group-II, 35% of group-III, and 20% of the control group (white soft petrolatum jelly) responded favorably. Side effects in the form of dermatitis and hyperpigmentation were seen in group-III. However, no patient discontinued from the study.

Conclusion: We conclude that both topical steroids and tretinoin were fairly effective in limited variant of alopecia areata.

Keywords: Alopecia areata, anthralin, topical steroids, tretenoin hai rloss hair loss treatment

Introduction

Alopecia areata is a non- scarring, recurrent, sometimes treatment-refractory hair disease, which can potentially cause hair loss in any hair bearing area. Alopecia areata commonly presents as patches of hair loss, of all scalp hair, (alopecia totalis), loss of body hair (alopecia universalis), or an ophiasis (band like) pattern. Common diseases associated with alopecia areata include allergic rhinitis, asthma, atopic dermatitis, and thyroid disorders.[1] It has also been associated with other diseases, most of which are autoimmune in nature e.g. vitiligo, lupus erythematosus, rheumatoid arthritis, pernicious anemia, scleroderma, ulcerative colitis, and diabetes mellitus....

edited for hair loss blog use

Prevention of chemotherapy-induced Hair loss.....
Jimenez JJ,.et al

edited for hair loss

Alopecia (hair loss) is experienced by thousands of cancer patients every year. Substantial-to-severe hairloss is induced by anthracyclines, taxanes, alkylating compounds, etc. Currently, no treatment appears to be generally effective in reliably preventing hair loss due to chemotherapy. We observed in experiments using different rodent models that localized administration of heat or subcutaneous/intradermal injection of geldanamycin or 17-(allylamino)-17-demethoxygeldanamycin induced a stress protein response in hair follicles and effectively prevented hair loss from adriamycin,.....

Alopecia (hair loss) is arguably the most feared side effect of cancer chemotherapy. Despite substantial efforts, no reliable and generally effective preventative treatment has become available. Scalp tourniquets and cooling devices have been utilized for decades to restrict blood flow to the scalp during chemotherapy treatment. Although such treatments were found to be successful in reducing alopecia in connection with certain chemotherapy regimens, they were difficult to standardize and not generally useful over the wide range of pharmacological regimens used in the clinic. Although more recent studies utilizing improved hypothermia devices reported increased reliability, certain antineoplastic drug combinations, notably combinations comprising a taxane could not be protected against. Among the many pharmacological approaches for alopecia prevention that were investigated, vitamin D3 appeared to be the most promising protective compound because it was effective against several different antineoplastic agents in preclinical experiments. However, a clinical trial was ultimately unsuccessful.All cells possess protective mechanisms that increase their resistance to various adverse conditions. Perhaps best known is the ubiquitous stress protein (Hsp) response that involves the enhanced expression of classical stress proteins such as Hsp90, Hsp70, and Hsp25, and of certain other proteins such as P-glycoprotein, in response to physical or chemical stresses. Elevated levels of Hsps are known to result in increased stress tolerance. The spectrum of toxicants an activated stress protein response can mitigate against is broad. As shown by previous studies, elevated levels of the cohort of Hsps or of individual Hsps are also protective against cytotoxicity from many antineoplastic agents used in the clinic. Table 1 summarizes selected studies relating to the reduction or prevention of toxicity from adriamycin, cyclophosphamide, taxol, and etoposide. Because the stress protein response is an intracellular protective mechanism, it should be possible to locally activate a stress protein response in noncancerous tissues without affecting the cytotoxic effects of an antineoplastic agent in cancerous tissues. We hypothesized that localized activation of a stress protein response in the hair follicles of a patient’s scalp (and eyebrows) would prevent chemotherapy-induced hair loss and that this protective effect could be achieved without reduction of tumor therapy efficacy......

hair regrowth blog

Redox cell signaling is an important process in regrowth of hair loss and in the action of hair loss treatment agents such as minoxidil.